Drug Profile
Research programme: diabetes therapy - Aventis/Deinove
Alternative Names: diabetes therapy research programme - Aventis/DeinoveLatest Information Update: 07 Feb 2019
Price :
$50
*
At a glance
- Originator Aventis; Morphochem AG
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 04 Sep 2003 No development reported - Preclinical for Diabetes mellitus in Germany (unspecified route)
- 15 Oct 2002 Preclinical trials in Diabetes mellitus in Germany (unspecified route)